Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy

Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén, Peter Ellmark

Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review


Introduction: CD40 signaling activates dendritic cells leading to improved T cell priming against tumor antigens. CD40 agonism expands the tumor-specific T cell repertoire and has the potential to increase the fraction of patients that respond to established immunotherapies. Areas covered: This article reviews current as well as emerging CD40 agonist therapies with a focus on antibody-based therapies, including next generation bispecific CD40 agonists. The scientific rationale for different design criteria, binding epitopes, and formats are discussed. Expert opinion: The ability of CD40 agonists to activate dendritic cells and enhance antigen cross-presentation to CD8+ T cells provides an opportunity to elevate response rates of cancer immunotherapies. While there are many challenges left to address, including optimal dose regimen, CD40 agonist profile, combination partners and indications, we are confident that CD40 agonists will play an important role in the challenging task of reprogramming the immune system to fight cancer.

Sidor (från-till)1635-1646
TidskriftExpert Opinion on Biological Therapy
Tidigt onlinedatum2021
StatusPublished - 2021

Ämnesklassifikation (UKÄ)

  • Immunologi inom det medicinska området


Utforska forskningsämnen för ”Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här